Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone for acute chest pain
NCT06949059Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydromorphone, sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Pain Relief at 30 Minutes After Administration. Started Jan 2025; status: recruiting.
02
Drugs
hydromorphone
Beyond the preview
Go deeper on NCT06949059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06949059.